» Articles » PMID: 28202614

Virus-Specific CD8 T Cells Infiltrate Melanoma Lesions and Retain Function Independently of PD-1 Expression

Overview
Journal J Immunol
Date 2017 Feb 17
PMID 28202614
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

It is well known that CD8 tumor-infiltrating lymphocytes (TILs) are correlated with positive prognoses in cancer patients and are used to determine the efficacy of immune therapies. Although it is generally assumed that CD8 TILs will be tumor-associated Ag (TAA) specific, it is unknown whether CD8 T cells with specificity for common pathogens also infiltrate tumors. If so, the presence of these T cells could alter the interpretation of prognostic and diagnostic TIL assays. We compared TAA-specific and virus-specific CD8 T cells in the same tumors using murine CMV, a herpesvirus that causes a persistent/latent infection, and vaccinia virus, a poxvirus that is cleared by the host. Virus-specific CD8 TILs migrated into cutaneous melanoma lesions during acute infection with either virus, after a cleared vaccinia virus infection, and during a persistent/latent murine CMV infection. Virus-specific TILs developed independently of viral Ag in the tumor and, interestingly, expressed low or intermediate levels of full-length PD-1 in the tumor environment. Importantly, PD-1 expression could be markedly induced by Ag but did not correlate with dysfunction for virus-specific TILs, in sharp contrast to TAA-specific TILs in the same tumors. These data suggest that CD8 TILs can reflect an individual's immune status, rather than exclusively representing TAA-specific T cells, and that PD-1 expression on CD8 TILs is not always associated with repeated Ag encounter or dysfunction. Thus, functional virus-specific CD8 TILs could skew the results of prognostic or diagnostic TIL assays.

Citing Articles

Computational immune synapse analysis reveals T-cell interactions in distinct tumor microenvironments.

Wang V, Liu Z, Martinek J, Foroughi Pour A, Zhou J, Boruchov H Commun Biol. 2024; 7(1):1201.

PMID: 39341903 PMC: 11438971. DOI: 10.1038/s42003-024-06902-2.


Intratumor injection of BCG Ag85A high-affinity peptides enhanced anti-tumor efficacy in PPD-positive melanoma.

Qin L, Zhang G, Wu Y, Yang Y, Zou Z Cancer Immunol Immunother. 2024; 73(6):103.

PMID: 38630135 PMC: 11024071. DOI: 10.1007/s00262-024-03693-7.


Cytotoxic CD4 T cells in chronic viral infections and cancer.

Malyshkina A, Bruggemann A, Paschen A, Dittmer U Front Immunol. 2023; 14:1271236.

PMID: 37965314 PMC: 10642198. DOI: 10.3389/fimmu.2023.1271236.


Memory T Cells in the Immunoprevention of Cancer: A Switch from Therapeutic to Prophylactic Approaches.

Mittra S, Harding S, Kaech S J Immunol. 2023; 211(6):907-916.

PMID: 37669503 PMC: 10491418. DOI: 10.4049/jimmunol.2300049.


The High Presence of HCMV pp71 Proteins, Correlate with P63 Expression in Pancreatic Cancer Tumor Tissue.

Abdul-Razzaq L, Ali Jassim M, Mahmood M Asian Pac J Cancer Prev. 2023; 24(4):1443-1447.

PMID: 37116169 PMC: 10352725. DOI: 10.31557/APJCP.2023.24.4.1443.


References
1.
Snyder C, Cho K, Bonnett E, van Dommelen S, Shellam G, Hill A . Memory inflation during chronic viral infection is maintained by continuous production of short-lived, functional T cells. Immunity. 2008; 29(4):650-9. PMC: 2583440. DOI: 10.1016/j.immuni.2008.07.017. View

2.
Liang S, Latchman Y, Buhlmann J, Tomczak M, Horwitz B, Freeman G . Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol. 2003; 33(10):2706-16. DOI: 10.1002/eji.200324228. View

3.
Restifo N, Dudley M, Rosenberg S . Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012; 12(4):269-81. PMC: 6292222. DOI: 10.1038/nri3191. View

4.
Turula H, Smith C, Grey F, Zurbach K, Snyder C . Competition between T cells maintains clonal dominance during memory inflation induced by MCMV. Eur J Immunol. 2013; 43(5):1252-63. PMC: 4500790. DOI: 10.1002/eji.201242940. View

5.
Quinn M, Erkes D, Snyder C . Cytomegalovirus and immunotherapy: opportunistic pathogen, novel target for cancer and a promising vaccine vector. Immunotherapy. 2016; 8(2):211-21. PMC: 5619022. DOI: 10.2217/imt.15.110. View